> The FDA put Bristol-Myers Squibb ($BMY) and AbbVie's ($ABBV) immuno-oncology treatment for multiple myeloma, Empliciti (elotuzumab), on its priority review track. Release
> Amgen ($AMGN) and UCB said their osteoporosis treatment romosozumab topped Eli Lilly & Co.'s ($LLY) Forteo at increasing hip bone density in post-menopausal women at high risk of fracture. Release | More
> European regulators gave the green light to Novartis' ($NVS) first-in-class drug Revolade for patients with severe aplastic anemia. Release
> The FDA expanded approval for Merck & Co.'s ($MRK) chemotherapy-related nausea drug Emend for use in some children. Release
> Tesaro ($TSRO) won FDA approval for its first drug, Varubi, a treatment for chemo-related nausea and vomiting in adults. Release
> Allergan ($AGN) said the official FDA labeling on its anti-infective drug Teflaro was updated to support a shorter infusion time. Release
And Finally... Swiss authorities approved reimbursement of the Norgine liver drug Xifaxan. Release